2019 ISAKOS Biennial Congress ePoster #746
The Influence of Femoral Tunnel Length on Graft Rupture After Anterior Cruciate Ligament Reconstruction
Luiz Gabriel B. Guglielmetti, MD, PhD, São Paulo, SP BRAZIL
Victor M. Oliveira, MD, PhD, São Paulo, SP BRAZIL
Ricardo P.L. Cury, MD, São Paulo, SP BRAZIL
Nilson R. Severino, MD, São Paulo, SP BRAZIL
Osmar P. A. Camargo, MD, PhD, São Paulo, SP BRAZIL
Fabrício R. Severino, MD, São Paulo, SP BRAZIL
Marcos Mestriner, MD, São Paulo, SP BRAZIL
Leandro J. Aihara, MD, São Paulo, SP BRAZIL
Alfredo D. Netto, MD, São Paulo, SP BRAZIL
Santa Casa de São Paulo, São Paulo, SP, BRAZIL
FDA Status Not Applicable
Summary
Is the femoral tunnel lenght in ACL reconstruction related to re-ruputre of the graft?
Abstract
Purpose
The aim of the study is to evaluate patients who had short femoral tunnels compared to patients with longer tunnels to assess whether a short tunnel is a risk factor for poor prognosis and re-rupture.
Methods
A retrospective observational study was carried out with 80 patients who underwent ACL reconstruction with flexor tendons using the medial transportal or transtibial technique. Patients were divided according to the amount of graft within the tunnel: =1.5 cm versus >1.5 cm; =2 cm versus >2 cm; =2.5 cm versus >2.5 cm; and =1.5 cm vs. >2.5 cm. Patients were evaluated 2 years after surgery by physical examination (Lachman, pivot shift and anterior drawer tests), a KT1000 arthrometer, objective and subjective IKDC scores, the Lysholm test and re-ruptures.
Results
Of the 80 operated patients, 9 were lost to follow-up. Comparative assessment of the patients with the different amounts of graft within the tunnel indicated no significant differences in the outcomes evaluated, except for the Lachman test, which was higher in patients with tunnels with >2 cm of graft compared with those with tunnels with =2 cm.
Conclusion
The amount of graft within the femoral tunnel does not appear to be a risk factor for clinical instability of the knee or re-rupture of the graft.
Level of Evidence: Level III, case-control study